Analysis of Medicare drug plans reveals variance in value and in formularies' coverage
A Kaiser Family Foundation study examined formularies, drug costs, and utilization management tools in drug plans offered by 14 national and near-national organizations, which encompass 35 unique prescription drug plans that account for 1,222 of the 1,429 packages available to Medicare beneficiaries.
A Kaiser Family Foundation study examined formularies, drug costs, and utilization management tools in drug plans offered by 14 national and near-national organizations, which encompass 35 unique prescription drug plans that account for 1,222 of the 1,429 packages available to Medicare beneficiaries. Researchers studied a sample of 152 generic and brand-name drugs, selected to include drugs commonly used by Medicare beneficiaries and some less-common, high-cost drugs.
Findings included:
The full study by the Kaiser Family Foundation is available at: http:// http://www.kff.org/medicare/7489.cfm
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
